达安基因(002030) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 reached ¥2,154,425,892.76, representing a 50.97% increase compared to the same period last year[4] - Net profit attributable to shareholders for the same period was ¥926,665,124.63, an increase of 22.13% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥933,702,549.32, reflecting a 23.51% increase compared to the previous year[4] - The basic earnings per share for Q3 2021 was ¥0.6603, up 22.14% from the same period last year[4] - The net profit attributable to the parent company was approximately ¥2.52 billion, an increase from ¥1.54 billion in the previous period, representing a growth of 64%[48] - The total comprehensive income attributable to the parent company was approximately ¥2.52 billion, compared to ¥1.54 billion in the same period last year, reflecting a 64% increase[48] - Net profit for the current period was CNY 2,543,092,652.35, up from CNY 1,501,925,331.83 in the previous period, indicating a growth of approximately 69.5%[44] Assets and Liabilities - The total assets of the company as of the end of the reporting period were ¥9,122,383,378.15, a 36.15% increase from the end of the previous year[7] - The equity attributable to shareholders increased by 47.80% year-on-year, amounting to ¥6,308,992,149.69[7] - The company's total assets as of September 30, 2021, were CNY 9,122,383,378.15, compared to CNY 6,700,027,768.66 at the end of 2020, marking an increase of 36.5%[35] - The total liabilities increased to CNY 2,573,840,743.69 from CNY 2,185,370,908.42, marking a rise of about 17.7%[40] - The total amount of contract liabilities was CNY 109,837,249.27, compared to CNY 193,650,389.58 in the previous period, indicating a decrease of about 43.3%[40] - The total liabilities decreased by 96.37% for current non-current liabilities, reflecting reclassification to current borrowings[17] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥2,173,722,019.97, showing a significant increase of 91.85%[4] - The net cash flow from operating activities was approximately ¥2.17 billion, compared to ¥1.13 billion in the previous year, indicating a 92% increase[54] - Operating cash inflow from sales of goods and services reached approximately ¥4.93 billion, up from ¥2.84 billion, marking a 74% increase year-over-year[51] - The net cash flow from investment activities was approximately ¥316.91 million, a turnaround from a negative cash flow of ¥291.31 million in the previous year[54] - The net cash flow from financing activities was negative at approximately ¥612.78 million, compared to a negative cash flow of ¥466.46 million in the same period last year[56] Expenses - Research and development expenses surged by 148.74% to ¥271,199,877.50 from ¥109,030,757.27, indicating a stronger focus on innovation and R&D investment[18] - The company’s sales expenses increased by 61.60% to ¥617,472,307.60 from ¥382,103,612.54, in line with business growth[18] - Total operating costs amounted to CNY 2,623,660,194.06, compared to CNY 1,791,177,271.66 in the previous period, reflecting an increase of about 46.4%[41] Shareholder Information - The top two shareholders, Guangzhou Zhongda Holdings Co., Ltd. and Guangzhou Bioengineering Center Co., Ltd., hold 16.63% and 14.50% of shares, respectively, indicating strong institutional support[22] Market and Product Development - The company is actively pursuing new product registrations, having obtained multiple medical device registration certificates in recent months[29] - The company plans to expand its market presence through strategic partnerships and potential acquisitions in the healthcare sector[29] Inventory and Receivables - Accounts receivable increased by 52.48% to ¥2,280,112,464.86 from ¥1,495,395,013.86, reflecting the growth in operating revenue[17] - The company's inventory rose by 30.95% to ¥413,427,973.01 from ¥315,716,471.41, attributed to increased market demand[17] Other Financial Metrics - The weighted average return on net assets was 15.85%, a decrease of 9.61% compared to the previous year[4] - The company reported a decrease in other receivables by 40.90%, down to ¥22,820,083.37 from ¥38,610,847.88, due to improved collection efforts[17] - The company reported a significant increase in long-term equity investments, which reached CNY 793,624,297.75, up from CNY 676,372,913.89, a growth of 17.4%[35] Compliance and Standards - The third quarter report for 2021 was not audited[72] - The company continues to adopt the cumulative effect method for the initial application of the new leasing standards, impacting retained earnings and related financial statement items[68]